$GROY

Gold Royalty Corp. (GROY): Financial results for H1 2026

Gold Royalty Corp. (GROY) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Gold Royalty Reports record SIX-MONTH results with continued strong cash flow and EARNINGS growth Vancouver, British Columbia – August 5, 2026 – Gold Royalty Corp. (“ Gold Royalty ” or the “ Company ”) (NYSE American: GROY) is pleased to announce the filing of its op

Original reporting
Published Aug 5, 2026, 8:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 7:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$GROY
Bullish
high confidence
Mentioned
$GROY
Relevance
7/10
alphai data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$GROYBullishHigh
01

Why it matters

The earnings beat and raised guidance suggest stronger cash flow generation, likely prompting buying interest.

02

Market read

First‑hand earnings release provides fresh data for traders; impacts GROY and related royalty stocks.

03

What to watch

Potential dilution from future royalty acquisitions and reliance on a few key projects could limit upside.

Relevance 7/10Novelty 8/10Timing: immediate (earnings released Aug 5 2026)

Background

Gold Royalty Corp. (NYSE American: GROY) filed a Form 6‑K reporting its H1 2026 financial results and operational updates.

Company-level read

Ticker impact

$GROYBullishHigh confidence
Context

Gold Royalty Corp. reported H1 2026 earnings with revenue up 80% YoY and adjusted EBITDA up 137%, plus guidance of 7,500‑9,300 GEOs for 2026.

Expected impact

Potential short‑term rally of 5‑10% as investors price in higher cash flow and growth outlook.

Evidence & confidence

Record revenue growth, solid cash balance, no debt and a $150M credit facility provide financial flexibility; guidance remains above prior expectations.

Market effects

Positive for gold‑linked royalty and royalty‑focused mining sector, may lift peers with similar exposure.

Supports sentiment for US‑listed mining royalty stocks and could benefit broader commodity‑related ETFs.

Highlights strength in gold and copper markets, reinforcing bullish outlook for precious‑metal investors worldwide.

Counterpoint

If gold prices falter, royalty revenue could decline, making the current rally vulnerable.

Key entities

  • Gold Royalty Corp.

    Gold and copper royalty-focused mining company.

  • David Garofalo

    Chairman and CEO of Gold Royalty Corp.

Related articles

$GROYMed

Gold Royalty Q2 Earnings Call Highlights

Gold Royalty Corp (GROY) discussed its Q2 earnings call, saying its NSR royalty model is based on revenue and can be insulated from mine operating cost inflation. It maintained 2026 guidance of 7,500 to 9,300 GEOs, with 1H at 44% of the midpoint. It also outlined ramp-up and acquisition updates, including a $6.25M REN NSR add-on and new Nevada royalties.

$HYMed

Hyster-Yale’s (HY) Bookings Boom Meets A Widening Loss

Hyster-Yale (HY) reported Q2 results with bookings up 106% YoY to $680M, but a net loss of $31.6M. Revenue rose 2% QoQ to $812.9M, and operating cash flow turned positive at $17M. Management expects full-year bookings to exceed 2025, but warns of slow margin recovery due to competitive pricing and tariffs.

$MNDYHighAI 8/10

Why Monday.com Stock Popped in August

Monday.com (MNDY) stock rose 16% in August, despite initial investor concerns over its Q2 results. Revenue grew 22% YoY to $365M, and adjusted net income increased 13% to $65.6M. The company provided optimistic guidance for Q3 and 2026. A strong earnings report from Salesforce later in the month boosted investor sentiment in the CRM sector, benefiting Monday.com.

$AQSTMed

Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus

Aquestive Therapeutics (AQST) reported Q2 2026 results, staying on track to resubmit Anaphylm epinephrine film to the FDA in Q3 2026. Studies addressed FDA concerns, with improved packaging and labeling. Revenue rose 38% to $13.8M, but net loss widened to $22.9M. Cash reserves stand at $98.5M. The company also advanced its epinephrine prodrug platform and manufacturing business.

$CRMDMedAI 8/10

CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged

CorMedix (CRMD) reported Q2 revenue of $101.9M, up from $39.7M a year ago, with net income of $26M. Management raised adjusted EBITDA guidance but kept full-year revenue guidance unchanged. DefenCath and the Melinta portfolio drove growth, with new supply agreements signed. The company expects to submit an sNDA for REZZAYO in Q3. Operating expenses increased due to Melinta's costs and R&D spending. Hedge fund ownership rose, while short interest remained high at 22.30%.